Dianthus Therapeutics (Dianthus Therapeutics) Total Stockholders Equity : $372.69 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Total Stockholders Equity?

Dianthus Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $372.69 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Dianthus Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $12.70. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Dianthus Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Dianthus Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Dianthus Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Total Stockholders Equity Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Stockholders Equity

-17.25

73.66

168.87

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial			73.66	-	178.38	168.87	372.69

Dianthus Therapeutics (NAS:DNTH) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Dianthus Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(372.687	-	0)	/	29.3486
	=	12.70

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Dianthus Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.4	+	0.097)	/	372.687
	=	0.00

Dianthus Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023